https://orcid.org/0000-0001-8592-9262
Abstract
Preserving fertility is a vital concern for young women diagnosed with endometrial carcinoma. The clinical management of such patients is often disappointing. It is rare to have two consecutive successful pregnancies. We present a child-bearing-age woman who underwent fertility preservation therapy due to endometrial carcinoma. Following fertility preservation therapy, she underwent in vitro fertilization and embryo transfer. After receiving her first fresh embryo transfer, she successfully conceived and gave birth to a healthy child. Two years after the first embryo transfer and regular follow-up, she had another frozen embryo transfer of two cleavage embryos and successfully gave birth to another healthy baby. After the delivery of her second child, she underwent surgical treatment for endometrial carcinoma. For endometrial carcinoma patients who intend to preserve fertility, high-quality long-term follow-up and personalized treatment are necessary.
Plain Language Summary
In this case report, we share the story of one young woman who had endometrial cancer but desired to have children. She received fertility-sparing treatment and in vitro fertilization to increase her chances of conceiving. She successfully delivered a healthy child after the first embryo transfer. Two years later, she had another healthy child through a second frozen embryo transfer. Rigorous monitoring showed no cancer recurrence throughout the entire treatment. There are currently few reported cases of a patient with endometrial cancer successfully and safely giving birth twice through assisted reproductive technology. This case report emphasizes that, with personalized treatment and monitoring, endometrial cancer patients can have multiple pregnancies safely. In summary, this case report brings hope to young women with early-stage endometrial cancer who aspire to become mothers. With the right support, they can overcome the challenges of cancer and have their own babies.
Abbreviations
IVF, in vitro fertilization; EC, endometrial carcinoma; MPA, medroxyprogesterone acetate; LNG-IUDs, levonorgestrel-releasing intrauterine devices; GnRH-a, gonadotropin-releasing hormone agonist; ART, assisted reproductive technologies; IVF-ET, in vitro fertilization and embryo transfer; MRI, magnetic resonance imaging; AMH, anti-Mullerian hormone; HRT, hormone replacement therapy.
Data Sharing Statement
Please contact correspondence author for data requests.
Ethics Approval and Consent to Participate
This case report was reviewed and approved by the Ethics Committee of the Beijing Obstetrics and Gynecology Hospital, Capital Medical University, 2018-KY-015-01. Written informed consent was obtained from the participants.
Consent for Publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Author Contributions
JYW collected the patient data and wrote the first draft of the article. YF interpreted patient follow-up data and edited drafts. TC gathered materials and interpreted the patient data. YMW reviewed the patient’s surgery procedure, drafted figures, and reviewed the case report. XKY and ZMX critically reviewed and revised the manuscript. All authors contributed to data analysis, drafting or revising the article, have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.